Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.13
ANGO's Cash to Debt is ranked lower than
51% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.81 vs. ANGO: 0.13 )
ANGO' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.13

Equity to Asset 0.67
ANGO's Equity to Asset is ranked higher than
77% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ANGO: 0.67 )
ANGO' s 10-Year Equity to Asset Range
Min: 0.06   Max: 0.94
Current: 0.67

0.06
0.94
F-Score: 5
Z-Score: 1.78
M-Score: -2.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Revenue Growth (%) 5.20
ANGO's Revenue Growth (%) is ranked higher than
74% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. ANGO: 5.20 )
ANGO' s 10-Year Revenue Growth (%) Range
Min: 3.2   Max: 25.2
Current: 5.2

3.2
25.2
EBITDA Growth (%) 1.40
ANGO's EBITDA Growth (%) is ranked higher than
67% of the 238 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.40 vs. ANGO: 1.40 )
ANGO' s 10-Year EBITDA Growth (%) Range
Min: -33.8   Max: 31.3
Current: 1.4

-33.8
31.3
EPS Growth (%) -34.50
ANGO's EPS Growth (%) is ranked higher than
52% of the 242 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. ANGO: -34.50 )
ANGO' s 10-Year EPS Growth (%) Range
Min: -34.5   Max: 100
Current: -34.5

-34.5
100
» ANGO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ANGO Guru Trades in Q3 2013

Joel Greenblatt 16,031 sh (New)
Jim Simons 92,723 sh (+416.68%)
Chuck Royce 958,403 sh (+1.3%)
Mario Gabelli 110,000 sh (-24.14%)
» More
Q4 2013

ANGO Guru Trades in Q4 2013

Steven Cohen 161,069 sh (New)
Jim Simons 186,046 sh (+100.65%)
Joel Greenblatt Sold Out
Mario Gabelli 105,000 sh (-4.55%)
Chuck Royce 812,776 sh (-15.19%)
» More
Q1 2014

ANGO Guru Trades in Q1 2014

Steven Cohen 380,250 sh (+136.08%)
Chuck Royce 772,576 sh (-4.95%)
Mario Gabelli 95,000 sh (-9.52%)
Jim Simons 67,546 sh (-63.69%)
» More
Q2 2014

ANGO Guru Trades in Q2 2014

Jim Simons 92,000 sh (+36.2%)
Chuck Royce 839,013 sh (+8.6%)
Steven Cohen 41,300 sh (unchged)
Mario Gabelli 86,000 sh (-9.47%)
» More
» Details

Insider Trades

Latest Guru Trades with ANGO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Sold Out 0.01%$13.38 - $16.71 $ 14.11-8%0
Joel Greenblatt 2013-09-30 New Buy0.01%$10.9 - $13.55 $ 14.1120%16031
Mario Gabelli 2013-09-30 Reduce -24.14%$10.9 - $13.55 $ 14.1120%110000
Joel Greenblatt 2012-09-30 Sold Out 0.12%$10.41 - $12.66 $ 14.1123%0
Mario Gabelli 2012-09-30 Add 22.25%$10.41 - $12.66 $ 14.1123%165032
Joel Greenblatt 2012-03-31 Add 89.16%0.07%$12.22 - $14.63 $ 14.1117%140154
Joel Greenblatt 2011-09-30 Add 58.28%0.05%$12.81 - $15.44 $ 14.111%63774
Mario Gabelli 2011-09-30 Reduce -49.13%0.01%$12.81 - $15.44 $ 14.111%103000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 160.30
ANGO's P/E(ttm) is ranked higher than
60% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 34.60 vs. ANGO: 160.30 )
ANGO' s 10-Year P/E(ttm) Range
Min: 18.13   Max: 374.44
Current: 160.3

18.13
374.44
P/B 0.93
ANGO's P/B is ranked higher than
96% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. ANGO: 0.93 )
ANGO' s 10-Year P/B Range
Min: 0.64   Max: 6.67
Current: 0.93

0.64
6.67
P/S 1.41
ANGO's P/S is ranked higher than
85% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.80 vs. ANGO: 1.41 )
ANGO' s 10-Year P/S Range
Min: 1.03   Max: 5.62
Current: 1.41

1.03
5.62
PFCF 40.31
ANGO's PFCF is ranked higher than
70% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.20 vs. ANGO: 40.31 )
ANGO' s 10-Year PFCF Range
Min: 10.01   Max: 285.43
Current: 40.31

10.01
285.43
EV-to-EBIT 46.78
ANGO's EV-to-EBIT is ranked higher than
69% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.48 vs. ANGO: 46.78 )
ANGO' s 10-Year EV-to-EBIT Range
Min: 9.2   Max: 186
Current: 46.78

9.2
186
Shiller P/E 65.65
ANGO's Shiller P/E is ranked higher than
67% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ANGO: 65.65 )
ANGO' s 10-Year Shiller P/E Range
Min: 33.31   Max: 94.15
Current: 65.65

33.31
94.15
Current Ratio 2.11
ANGO's Current Ratio is ranked higher than
66% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. ANGO: 2.11 )
ANGO' s 10-Year Current Ratio Range
Min: 1.95   Max: 14.28
Current: 2.11

1.95
14.28
Quick Ratio 1.26
ANGO's Quick Ratio is ranked higher than
61% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.84 vs. ANGO: 1.26 )
ANGO' s 10-Year Quick Ratio Range
Min: 1.16   Max: 12.12
Current: 1.26

1.16
12.12

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.87
ANGO's Price/DCF (Projected) is ranked higher than
97% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.22 vs. ANGO: 0.87 )
ANGO' s 10-Year Price/DCF (Projected) Range
Min: 0.55   Max: 1.09
Current: 0.87

0.55
1.09
Price/Median PS Value 0.78
ANGO's Price/Median PS Value is ranked higher than
91% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. ANGO: 0.78 )
ANGO' s 10-Year Price/Median PS Value Range
Min: 0.61   Max: 2.89
Current: 0.78

0.61
2.89
Earnings Yield (Greenblatt) 2.10
ANGO's Earnings Yield (Greenblatt) is ranked higher than
53% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. ANGO: 2.10 )
ANGO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 10.9
Current: 2.1

0.5
10.9
Forward Rate of Return (Yacktman) -8.39
ANGO's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 260 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.14 vs. ANGO: -8.39 )
ANGO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -12.5   Max: 5.4
Current: -8.39

-12.5
5.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:UG2.Germany
AngioDynamics Inc. was incorporated in 1988 in Delaware. The Company designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company is organized in two segments: Vascular and Oncology/Surgery. The Oncology/Surgery Division includes Radiofrequency Ablation (RFA) and NanoKnife product lines. This division also includes the microwave ablation technology products obtained through the acquisition of Microsulis Medical Ltd. The Vascular division manages Fluid Management, Venous, AngioVac, Angiographic, PTA, Drainage, Thrombolytic, Micro Access Kits, Dialysis, PICC and Port product lines. The Company's product offering includes the NAMIC Fluid Management portfolio. The NAMIC product line includes an extensive offering of manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers and interventional accessories. The devices are utilized together and allow clinicians to aspirate or inject contrast, saline, remove waste and monitor invasive blood pressures throughout the procedure. The venous products consist of our VenaCure EVLT laser system and Sotradecol. The AngioVac devices are for use with other manufacturer's off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of a extracorporeal bypass procedure for up to six hours. Thrombolytic catheters are used to deliver thrombolytic agents, which are drugs that dissolve blood clots in hemodialysis access grafts, arteries, veins and surgical bypass grafts. The micro access sets provide interventional physicians a smaller introducer system for minimally-invasive procedures. Image-guided vascular access, or IGVA, involves the use of advanced imaging equipment to guide the placement of catheters that deliver primarily short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system. Radiofrequency Ablation (RFA) products use radiofrequency energy to provide a minimally invasive approach to ablating solid cancerous or benign tumors. The NanoKnife Ablation System is for the surgical ablation of soft tissue. The NanoKnife Ablation System utilizes low energy direct current electrical pulses to permanently open pores in target cell membranes. The treated tissue is then removed by the body's natural processes in a matter of weeks, mimicking natural cell death. The Acculis Microwave Tissue Ablation (MTA) System complements the full range of ablative technologies. The Company competes with Boston Scientific Corporation; Cook Medical; Cordis Corporation, a subsidiary of Johnson & Johnson, Inc.; C.R. Bard; Medical Components, Inc., or Medcomp; Arrow International, a subsidiary of TeleFlex Medical; Smith's Medical, a subsidiary of Smiths Group PLC; Vascular Solutions; Covidien subsidiaries (Kendall, VNUS, EV3) and M
» More Articles for ANGO

Headlines

Articles On GuruFocus.com
The Barclays Triggers More Insider Buying Mar 13 2013 
Weekly CEO Buys Highlight: JPM, ROG, PBY, ANGO, MCHX Jul 21 2012 
Weekly CEO Buys Highlight: WINA, ANGO, FES, LTS, TBOW Apr 15 2012 
Weekly CEO Buys Highlight: PKY, TWO, UVSP, AGYS, ANGO Feb 19 2012 
AngioDynamics Inc. Reports Operating Results (10-Q) Jan 07 2011 
AngioDynamics Inc. Reports Operating Results (10-Q) Oct 08 2010 
AngioDynamics Inc. Reports Operating Results (10-Q) Jan 08 2010 
AngioDynamics Inc. Reports Operating Results (10-Q) Oct 07 2009 
Weekly CEO Buys Highlight: CoBiz Financial Inc, Winmark Corp, The Greenbrier Companies Inc, AngioDyn Jul 26 2009 
Weekly CEO Buys Highlight: The Greenbrier Companies, AngioDynamics, Hallmark Financial Services, Ves Apr 18 2009 

More From Other Websites
ANGIODYNAMICS INC Financials Aug 22 2014
ANGIODYNAMICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Aug 14 2014
ANGIODYNAMICS INC Files SEC form 8-K, Change in Directors or Principal Officers Aug 08 2014
AngioDynamics to Present at Canaccord Genuity 34th Annual Growth Conference Aug 07 2014
AngioDynamics (ANGO) Crumbles: Stock Falls 7.4% Jul 25 2014
AngioDynamics Q4 Earnings Beat, Revenues Up on Higher Sales Jul 24 2014
ANGIODYNAMICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 23 2014
AngioDynamics Reports 2014 Fourth Quarter and Full Year Financial Results Jul 23 2014
Q4 2014 AngioDynamics Earnings Release - After Market Close Jul 23 2014
AngioDynamics Awarded Novation Innovative Technology Contract Covering BioFlo PICCs and BioFlo Ports Jul 21 2014
AngioDynamics to Report Fiscal 2014 Fourth Quarter and Full Year Financial Results Jul 08 2014
AngioDynamics' Celerity System Wins FDA Nod for PICC Jun 19 2014
Top Analyst Upgrades and Downgrades: Amazon, Celgene, Cisco, FedEx, Starbucks and More Jun 19 2014
AngioDynamics upgraded by Canaccord Genuity Jun 19 2014
AngioDynamics Announces FDA Clearance for Celerity Tip Location System Jun 18 2014
AngioDynamics Awarded Premier Inc.'s Supplier Horizon Award Jun 11 2014
Updated Research Report on AngioDynamics May 23 2014
AngioDynamics management to meet with Piper Jaffray May 14 2014
Weakness Seen in AngioDynamics (ANGO): Stock Tumbles 7.8% Apr 14 2014
AngioDynamics Delivering The Growth, Margins Next? Apr 11 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK